Immunome (IMNM) Cash & Equivalents (2019 - 2026)

Immunome's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $582.7 million for Q1 2026.

• Quarterly Cash & Equivalents rose 126.19% year-over-year to $582.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582.7 million (up 126.19% YoY) and the FY2025 annual result came in at $653.5 million, up 355.86% from the prior year.
• Cash & Equivalents was $582.7 million for Q1 2026 at Immunome, down from $653.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $653.5 million in Q4 2025 and bottomed at $20.3 million in Q4 2022.
• A 5-year average of $178.9 million and a median of $143.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 58.72% — and 2024, when it surged 507.16%.
• Immunome's Cash & Equivalents stood at $20.3 million in 2022, then jumped by 385.55% to $98.7 million in 2023, then soared by 45.27% to $143.4 million in 2024, then soared by 355.86% to $653.5 million in 2025, then dropped by 10.83% to $582.7 million in 2026.
• Business Quant data shows IMNM's Cash & Equivalents at $582.7 million in Q1 2026, $653.5 million in Q4 2025, and $272.6 million in Q3 2025.